CYP2AB1 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the CYP2AB1 enzyme, a member of the cytochrome P450 superfamily. This enzyme is part of a group of monooxygenases that play a critical role in the oxidative metabolism of a wide range of substrates, including various endogenous molecules like steroids, fatty acids, and exogenous compounds such as drugs and environmental chemicals. CYP2AB1, like other cytochrome P450 enzymes, functions by introducing an oxygen atom into its substrates, a process known as hydroxylation, which often leads to increased solubility and facilitates further metabolic processing or excretion. This enzyme is involved in the complex network of biochemical pathways that regulate the biotransformation and detoxification of both naturally occurring and foreign compounds in the body.
Inhibitors of CYP2AB1 are typically small molecules designed to bind to the active site of the enzyme, thereby preventing it from interacting with its natural substrates. These inhibitors may function by occupying the substrate-binding pocket, blocking access to the enzyme's catalytic core, or by inducing conformational changes that reduce the enzyme's catalytic efficiency. The development of CYP2AB1 inhibitors involves detailed structural analysis of the enzyme to identify key residues and binding motifs essential for its activity. By inhibiting CYP2AB1, researchers can dissect the specific role of this enzyme in various metabolic processes, understanding how it contributes to the overall function of the cytochrome P450 family. The study of CYP2AB1 inhibitors provides valuable insights into the enzyme's substrate specificity, its role in the metabolism of particular compounds, and its interaction with other metabolic enzymes. This research is crucial for understanding the diverse functions of cytochrome P450 enzymes and their impact on metabolic homeostasis, highlighting the intricate balance maintained by these enzymes in processing a vast array of chemical entities within biological systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole, a direct inhibitor of CYP2AB1, impacts its oxidoreductase and steroid hydroxylase activities. Its role in xenobiotic metabolism highlights its potential in modulating cellular responses. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Clotrimazole acts as a direct inhibitor of CYP2AB1, affecting its oxidoreductase and steroid hydroxylase activities. Its modulation of cellular pathways, particularly in xenobiotic metabolism, is noteworthy. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole directly inhibits CYP2AB1, impacting its heme binding and oxidoreductase activities. Its role in xenobiotic metabolic processes underscores its significance in modulating cellular functions. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $66.00 $160.00 | 2 | |
Miconazole is a direct inhibitor of CYP2AB1, affecting its oxidoreductase and steroid hydroxylase activities. Its influence on organic acid and xenobiotic metabolism highlights its potential pharmacological impact. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
Itraconazole acts as a direct inhibitor of CYP2AB1, influencing its heme binding and oxidoreductase activities. Its role in xenobiotic metabolic processes underscores its potential in modulating cellular responses. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine is a direct inhibitor of CYP2AB1, affecting its oxidoreductase and steroid hydroxylase activities. Its impact on cellular pathways, particularly in xenobiotic metabolism, is noteworthy. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine is a direct inhibitor of CYP2AB1, influencing its heme binding and oxidoreductase activities. Its modulation of organic acid and xenobiotic metabolic processes underscores its pharmacological relevance. | ||||||
Metronidazole | 443-48-1 | sc-204805 sc-204805A | 5 g 25 g | $84.00 $205.00 | 11 | |
Metronidazole acts as a direct inhibitor of CYP2AB1, affecting its oxidoreductase and steroid hydroxylase activities. Its influence on xenobiotic metabolism highlights its potential pharmacological impact. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Terbinafine is a direct inhibitor of CYP2AB1, influencing its heme binding and oxidoreductase activities. Its modulation of xenobiotic metabolism underscores its potential pharmacological impact. | ||||||